Literature DB >> 21910721

Primary refractory acute myeloid leukaemia - in search of better definitions and therapies.

Farhad Ravandi1.   

Abstract

The definition of primary refractory acute myeloid leukaemia is the failure to achieve a response after one or two cycles of induction. Given that there are many different strategies involving different doses of cytarabine and anthracyclines, which may or may not be equivalent, and as this is an area of unmet need with the potential for the development of new agents and strategies, uniform criteria for response have been described that need to be adhered to. The outcome of patients with chemoresistant disease is poor with only a proportion of patients salvaged by allogeneic stem cell transplantation. Progress in supportive care strategies and donor identification has enabled more of these patients to undergo unrelated donor transplantation. Novel strategies and new agents directed at the biology of the disease and the mechanisms of resistance are needed.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21910721      PMCID: PMC4090682          DOI: 10.1111/j.1365-2141.2011.08869.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  40 in total

1.  Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.

Authors:  W Plunkett; J O Liliemark; E Estey; M J Keating
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

2.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Authors:  Jan Krönke; Richard F Schlenk; Kai-Ole Jensen; Florian Tschürtz; Andrea Corbacioglu; Verena I Gaidzik; Peter Paschka; Shiva Onken; Karina Eiwen; Marianne Habdank; Daniela Späth; Michael Lübbert; Mohammed Wattad; Thomas Kindler; Helmut R Salih; Gerhard Held; David Nachbaur; Marie von Lilienfeld-Toal; Ulrich Germing; Detlef Haase; Hans-Günther Mergenthaler; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

3.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.

Authors:  C P Leith; K J Kopecky; I M Chen; L Eijdems; M L Slovak; T S McConnell; D R Head; J Weick; M R Grever; F R Appelbaum; C L Willman
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

Review 4.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

Authors:  B D Cheson; P A Cassileth; D R Head; C A Schiffer; J M Bennett; C D Bloomfield; R Brunning; R P Gale; M R Grever; M J Keating
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

5.  Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kellie J Archer; Mark J Pettenati; Nyla A Heerema; Andrew J Carroll; Prasad R K Koduru; Jonathan E Kolitz; Lisa J Sterling; Colin G Edwards; John Anastasi; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

6.  A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome.

Authors:  H C Fung; A Stein; M l Slovak; M R O'donnell; D S Snyder; S Cohen; D Smith; A Krishnan; R Spielberger; R Bhatia; S Bhatia; P Falk; A Molina; A Nademanee; P Parker; R Rodriguez; J Rosenthal; R Sweetman; N Kogut; F Sahebi; L Popplewell; N Vora; G Somlo; K Margolin; W Chow; E Smith; S J Forman
Journal:  Biol Blood Marrow Transplant       Date:  2003-12       Impact factor: 5.742

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy.

Authors:  J C Biggs; M M Horowitz; R P Gale; R C Ash; K Atkinson; W Helbig; N Jacobsen; G L Phillips; A A Rimm; O Ringdén
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

9.  Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.

Authors:  Wolfgang Kern; Torsten Haferlach; Claudia Schoch; Helmut Loffler; Winfried Gassmann; Achim Heinecke; Maria Christina Sauerland; Wolfgang Berdel; Thomas Buchner; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

10.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.

Authors:  J F Bishop; J P Matthews; G A Young; J Szer; A Gillett; D Joshua; K Bradstock; A Enno; M M Wolf; R Fox; R Cobcroft; R Herrmann; M Van Der Weyden; R M Lowenthal; F Page; O M Garson; S Juneja
Journal:  Blood       Date:  1996-03-01       Impact factor: 22.113

View more
  16 in total

1.  Allogeneic transplantation in primary refractory AML.

Authors:  P Ferguson; C Craddock
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 2.  Management of primary refractory acute myeloid leukemia in the era of targeted therapies.

Authors:  Christine M McMahon; Alexander E Perl
Journal:  Leuk Lymphoma       Date:  2018-09-20

3.  An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Authors:  Paul Ferguson; Robert K Hills; Angela Grech; Sophie Betteridge; Lars Kjeldsen; Michael Dennis; Paresh Vyas; Anthony H Goldstone; Donald Milligan; Richard E Clark; Nigel H Russell; Charles Craddock
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

4.  Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Authors:  M Wattad; D Weber; K Döhner; J Krauter; V I Gaidzik; P Paschka; M Heuser; F Thol; T Kindler; M Lübbert; H R Salih; A Kündgen; H-A Horst; P Brossart; K Götze; D Nachbaur; C-H Köhne; M Ringhoffer; G Wulf; G Held; H Salwender; A Benner; A Ganser; H Döhner; R F Schlenk
Journal:  Leukemia       Date:  2017-01-19       Impact factor: 11.528

Review 5.  Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.

Authors:  B Gyurkocza; H M Lazarus; S Giralt
Journal:  Bone Marrow Transplant       Date:  2017-02-27       Impact factor: 5.483

6.  Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.

Authors:  Megan Othus; Frederick R Appelbaum; Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Thomas Nevill; Joseph Brandwein; Richard A Larson; Patrick J Stiff; Roland B Walter; Martin S Tallman; Leif Stenke; Harry P Erba
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-20       Impact factor: 5.742

7.  Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Authors:  Mohamad Mohty; Florent Malard; Didier Blaise; Noel Milpied; Gérard Socié; Anne Huynh; Oumédaly Reman; Ibrahim Yakoub-Agha; Sabine Furst; Thierry Guillaume; Resa Tabrizi; Stéphane Vigouroux; Pierre Peterlin; Jean El-Cheikh; Philippe Moreau; Myriam Labopin; Patrice Chevallier
Journal:  Haematologica       Date:  2016-08-25       Impact factor: 9.941

8.  Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from A Developing Country.

Authors:  Tariq Ghafoor; Sumaira Khalil; Tanzeela Farah; Shakeel Ahmed; Imtenan Sharif
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-09

9.  Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.

Authors:  Farhad Ravandi; Jeffrey Jorgensen; Gautam Borthakur; Elias Jabbour; Tapan Kadia; Sherry Pierce; Mark Brandt; Sa Wang; Sergej Konoplev; Xuemei Wang; Xuelin Huang; Naval Daver; Courtney DiNardo; Michael Andreeff; Marina Konopleva; Zeev Estrov; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2016-09-22       Impact factor: 6.860

10.  Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).

Authors:  Ulf Schnetzke; Peter Fix; Baerbel Spies-Weisshart; Karin Schrenk; Anita Glaser; Hans-Joerg Fricke; Paul La Rosée; Andreas Hochhaus; Sebastian Scholl
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-12       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.